Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

GlobeNewswire May 4, 2023

Dennis Huang of Ultragenyx Named to MassBio's Board of Directors

GlobeNewswire April 28, 2023

Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update

GlobeNewswire April 27, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 19, 2023

Ultragenyx to Present at Guggenheim's Genomic Medicines and Rare Disease Days

GlobeNewswire March 28, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 21, 2023

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

GlobeNewswire March 14, 2023

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

GlobeNewswire February 28, 2023

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

GlobeNewswire February 16, 2023

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

GlobeNewswire February 9, 2023

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

GlobeNewswire January 6, 2023

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 21, 2022

Ultragenyx to Present at Piper Sandler Healthcare Conference

GlobeNewswire November 22, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 18, 2022

Ultragenyx Announces Departure of Chief Financial Officer

GlobeNewswire November 10, 2022

Ultragenyx to Present at Upcoming Healthcare Conferences

GlobeNewswire November 9, 2022

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

GlobeNewswire November 2, 2022

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

GlobeNewswire October 27, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2022